2020-2026年医药授权协议趋势

本报告对全球医药产业的授权协议进行了全面分析。报告专为业务拓展、许可、法律和策略专业人士设计，深入剖析了企业如何建立许可合作关係、协商财务条款以及共享研发和商业化权利。

这份经过全面修订和更新的报告包含了2020年至2026年间签署的2700多份许可协议的详细信息，全面展现了医药行业的许可活动。每份协议记录均包含可用的财务条款，并在公开的情况下提供指向线上协议记录和已提交给监管机构的协议文件的连结。

透过整合详细的交易数据、财务基准以及对实际协议文件的访问，本报告为您提供宝贵的见解，帮助您评估潜在合作伙伴、制定许可协议并协商更有利的条款。

主要优势

• 显着缩短研究时间

集中存取超过 2,700 份授权协议，无需再搜寻多个资料库、新闻稿和监管文件。

• 许可协议结构基准分析

了解製药公司如何建构其许可合作关係，包括研发责任、区域权利和商业化安排。

• 财务条款分析

审查已揭露的付款结构，例如预付款、里程碑付款和特许权使用费，以准确评估许可协议的价值。

• 存取实际合约文件

审查已向美国证券交易委员会 (SEC) 提交的实际许可协议（如有），以深入了解实际协议背后的合约条款。

• 识别拥有有效许可协议的公司

识别在医药许可领域最活跃的公司，并分析其合作策略。

• 追踪许可趋势

分析自 2020 年以来依公司、治疗领域和技术划分的授权活动，以了解产业合作策略的演变。

目录

摘要整理

第一章：引言

第二章：许可交易趋势

• 许可协议的定义
• 2020年以来授权协议的趋势
  • 依年份
  • 依研发阶段
  • 依行业
  • 依治疗领域
  • 依技术型
  • 最活跃的公司
• 签订许可合作协议的原因
• 许可协议的未来

第三章：许可协议结构概述

• 许可协议的结构许可协议

第四章 主要授权协议

• 主要授权协议：依金额排序

第五章：最活跃的25项授权协议

• 最活跃的25项授权协议

第六章：合作协议目录：附协议文件

• 合作协议：附协议文件
• 合约目录
• 合约目录 - 依公司（A-Z）排序
• 合约目录 - 依治疗领域排序
• 合约目录 - 依技术排序
• 关于Biopharma Research Ltd
• 当前合作关係
• 当前协议
• 近期合作报告标题

Benchmark Licensing Partnerships Across the Global Pharmaceutical Industry

Request our free report sample

The Licensing Deals in Pharmaceuticals 2020-2026 report provides a comprehensive analysis of licensing agreements across the global pharmaceutical industry. Designed for business development, licensing, legal, and strategy professionals, the report delivers detailed insight into how companies structure licensing partnerships, negotiate financial terms, and allocate development and commercialization rights.

Fully revised and updated, the report includes details of more than 2,700 licensing deals announced between 2020 and 2026, providing an extensive view of licensing activity across the pharmaceutical sector. Each deal record includes financial terms where available and links to online deal records and contract documents filed with regulators when publicly disclosed.

By combining detailed deal data, financial benchmarking, and access to real contract documents, the report provides valuable intelligence for evaluating potential partners, structuring licensing agreements, and negotiating stronger deal terms.

Key Benefits

• Save Significant Research Time

Access over 2,700 licensing deals in a single resource, eliminating the need to search multiple databases, press releases, and regulatory filings.

• Benchmark Licensing Deal Structures

Understand how pharmaceutical companies structure licensing partnerships, including development responsibilities, territorial rights, and commercialization arrangements.

• Analyze Financial Terms with Confidence

Review disclosed payment structures such as upfront payments, milestone payments, and royalties, enabling accurate benchmarking of licensing deal value.

• Access Real Contract Documents

Where available, explore actual licensing agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.

• Identify Active Licensing Dealmakers

Discover which companies are most active in pharmaceutical licensing and analyze their partnership strategies.

• Track Licensing Trends

Analyze licensing activity since 2020 across companies, therapeutic areas, and technologies to understand how industry partnering strategies are evolving.

What's Included in the Report

Analysis of pharmaceutical licensing dealmaking trends since 2020

Overview of licensing deal structures and financial models

Review of leading licensing deals by disclosed value

Profiles of the most active licensing dealmakers

Detailed analysis of deals by company, therapeutic area, and technology type

A comprehensive deal directory covering all licensing deals announced since 2020

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual licensing contracts, the report allows users to evaluate key partnership provisions such as:

• Rights granted or optioned under the license
• Upfront payments, milestone payments, and royalty structures
• Intellectual property ownership and licensing scope
• Development, manufacturing, and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration and termination provisions
• Why This Report Matters
• Licensing agreements are a cornerstone of pharmaceutical innovation, enabling companies to access new technologies, share development risk, and accelerate product commercialization.
• By providing comprehensive deal data, financial benchmarking, and access to real contract documents, this report delivers the intelligence needed to structure stronger licensing partnerships and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2020
  • 2.3.1. Licensing dealmaking by year
  • 2.3.2. Licensing dealmaking by phase of development
  • 2.3.3. Licensing dealmaking by industry sector
  • 2.3.4. Licensing dealmaking by therapy area
  • 2.3.5. Licensing dealmaking by technology type
  • 2.3.6. Licensing dealmaking by most active company
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements
• Figure 3: Licensing deals signed at each phase of development
• Figure 4: Licensing deals by industry sector
• Figure 5: Licensing deals by therapy area
• Figure 6: Licensing deals by technology type
• Figure 7: Top 25 most active licensing dealmakers
• Figure 8: Top licensing deals by value
• Figure 9: Most active licensing dealmakers